Data are available from the French Caisse Nationale de l'Assurance Maladie (CNAM) for researchers who meet the criteria for access to confidential data. These are edicted by the French national commission governing the application of data privacy laws (the Commission Nationale Informatique et Libertés). Consequently, data are available after obtaining legal authorization from the French Institut des Données de Santé (at <https://www.indsante.fr/>) and from the French national commission governing the data privacy laws (Commission Nationale Informatique et Liberté; CNIL, <https://www.cnil.fr/>).

Introduction {#sec001}
============

Zolpidem, a hypnotic drug marketed in France since 1987 (Stilnox^®^) is an imidazopyridine which binds to the benzodiazepine binding site on the GABA-A receptors. It is highly selective for the α1 subtype receptor and initial clinical trials reported no evidence of abuse or dependence \[[@pone.0228495.ref001],[@pone.0228495.ref002]\]. As a consequence, zolpidem has been marketed as a safer drug than benzodiazepines, particularly regarding dependence issues.

The first case report describing dependence on zolpidem appeared in the literature in 1993 \[[@pone.0228495.ref003]\]. The French health authorities (National Agency for Medicines and Health Products Safety; ANSM) launched an official study in 2002 to evaluate the dependence potential of zolpidem. This study was conducted by Nantes Centre for Evaluation and Information on Pharmacodependence (CEIP). The 3 main CEIP missions are to collect data and assess the dependence potential of the identified psychoactive drugs, to provide information on the risk of abuse or dependence on psychoactive substances, and to conduct research. The results highlighted the high dependence potential of zolpidem and identified 2 distinct populations among dependent patients. The first type seeks paradoxical stimulant effects by taking high doses during the day. The second type includes dependent patients who have been treated for insomnia, but who, given the short half-life and tolerance, have increased their doses \[[@pone.0228495.ref004]\]. As a result, the summary of product characteristics of zolpidem was comprehensively modified in 2004, with the inclusion of the sentence: "A pharmacodependence may materialize even at therapeutic doses, and/or for subjects who do not show an individualized risk factor" \[[@pone.0228495.ref001]\]. In June 2012, an update of these data found the same results, but suggested escalation in number and gravity of cases, with particularly high dose intake. Moreover, zolpidem has been more and more involved in forged prescription sheets, being present in 29% of cases of forgery reported in the French survey of Suspect Prescriptions Possibly Indicating Abuse (OSIAP for "*Ordonnances Suspectes Indicateur d'Abus Possible*" in French) over the 2009 to 2012 period \[[@pone.0228495.ref005]\].

In light of these results, the prescription of zolpidem on secure prescription pads has been put forward by the French National Commission on Narcotics and Psychotropic Substances. Secured prescription pads contain specific prescription sheets that are protected against forgery and that must be used by physicians when prescribing narcotics. On the 11th of January 2017, the ANSM decreed that as from April the 10th 2017, the prescription of zolpidem was to be done with such secured prescription pads in order to limit the risk of abuse and misuse. Moreover, such prescription must now display the number of therapeutic units, quantity and dosage written in full and for a maximum duration of 28 days. The objective of the ZORRO study (ZOlpidem and the Reinforcement of the Regulation of prescription Orders) was to evaluate the overall impact of the obligation to use secure prescription pads for zolpidem. The present work aimed at evaluating the impact of this measure on the number of zolpidem consumers.

Materials and methods {#sec002}
=====================

Experimental design {#sec003}
-------------------

This study was an observational prospective study using the French healthcare data system (SNDS)\[[@pone.0228495.ref006]\], conducted by the Nantes University Hospital Addictovigilance department. The study was founded by a grant from the ANSM (AAP-2017-027) and was monitored by a pluridisciplinary steering committee with pharmacologists, psychiatrists specialized in addiction, pharmacoepidemiologist and general practioners (GP).

Participants and outcomes {#sec004}
-------------------------

The study sample included all patients in the Generalist Sample of Beneficiaries (EGB). EGB is a 1/97^th^ representative sampling of the SNDS. The SNDS links several existing databases: the nationwide claims database of the French National Healthcare system (*Système National d'Informations Interrégimes de l'Assurance Maladie; SNIIRAM)*; the national hospital database (Programme de Médicalisation des Systèmes d'Information; PMSI) and the national death registry (Centre d\'épidémiologie sur les causes médicales de Décès; CepiDC). The SNDS covers more than 98% of the French population (66 million people) from birth (or immigration) to death (or emigration), even in case of change in occupation or retirement. Data are individual and anonymous. The SNDS contains a longitudinal record of health encounters, hospital diagnoses and drugs deliveries relative to outpatient medical care claims, including all reimbursed drugs, information from hospital discharge summaries, and date of death.

The primary outcome was to quantify the number of zolpidem consumers and the rate of zolpidem treatment initiation before and after the implementation of the secured prescription. The secondary outcome was the identification of factors associated with zolpidem consumption after the change in law.

Data collection {#sec005}
---------------

The target population of our research was consumers of zolpidem included in the EGB aged over 18 years old. A prevalent user was defined as a patient being reimbursed at least once for zolpidem and an incident episode of zolpidem use was defined as a patient receiving a first delivery of zolpidem without any prior deliveries over the preceding 6 months.

Two time periods were used: *(i)* period 1 from July 1, 2016 to January 1, 2017, reflecting zolpidem consumption before the change in law *(ii)* period 2 from July 1, 2017 to January 1, 2018 reflecting the steady state of zolpidem consumption after the change in law.

The variables gathered in the database included age at inclusion, sex, information on active CMUc (for "Couverture médicale universelle complémentaire", which indicates low-income status granting full reimbursement of health expenditures), and the presence of a chronic disease *via* registration in the list of chronic diseases scheme beneficiaries (ALD for "Affections de Longue Durée").

Ethical issues {#sec006}
--------------

This study was approved by the French Committee of Protection of Persons (*Comité de Protection des Personnes*, CPP, approval reference 2018-A01070-35) and the National Data Protection and Freedoms Committee (approval reference 918201). The study was registered on [www.clinicaltrial.gov](http://www.clinicaltrial.gov) under the reference NCT03584542. The study protocol is available as an open publication \[[@pone.0228495.ref007]\].

Statistical analysis {#sec007}
--------------------

Prevalences were described with their point estimates and 95% accuracy intervals. The comparison of prevalences between both periods was performed with a McNemar test. Let's consider probabilities of respectively stopping treatment in period 2 when you are a consumer in period 1(p~stop~) and starting treatment in period 2 when you did not consume in period 1 (p~start~). The null hypothesis of the test is p~stop~ equal p~start~. The alpha risk was set at 5% and the statistical significance threshold set at 5%. This analysis was done on the dataset containing only patients present in the EGB database over the 2 periods. A sensitivity analysis was conducted by recoding patients missing in a period as non-consumers in the period considered. Incidences were first described by constructing rates of treatment initiations per 100,000 insured per month (patient-month). The description of incidences trends was then conducted through the construction of incidence rate ratios (IRRs) adjusted for the time period with a negative binomial model.

In order to study effects of potential confounders of the effect of change in law, a logistic regression was conducted. The variables to be included in the model were defined *a priori* and included period (before vs after change in law), age in 2016, sex, being under a CMUc scheme or an ALD scheme. Age was introduced into the model in class intervals because the hypothesis of a constant effect of aging on the probability of receiving zolpidem regardless of the age stratum in which patients are located was unlikely to be respected for this variable. The adequacy of the model to the data was checked graphically. The dependencies between observations in a same patient over the two time periods were handled by the use of Generalized Estimating Equations (GEE), with the use of a robust variance estimator in order to facilitate convergence and improve the accuracy of confidence intervals. All analyses were performed with SAS 9.4 (SAS Institute, North Carolina, USA).

Results {#sec008}
=======

Study participant description {#sec009}
-----------------------------

The characteristics of the population present in the database each year are described in [Table 1](#pone.0228495.t001){ref-type="table"}. Albeit an overall increase in the population size is observed, the characteristics remained similar between the two periods, with a population showing a sex ratio of 0.96, aged 41 years on average at inclusion, one sixth benefiting from the ALD scheme and 6% benefiting from a CMUc scheme.

10.1371/journal.pone.0228495.t001

###### Characteristics of the population.

![](pone.0228495.t001){#pone.0228495.t001g}

  Period                               July 1, 2016 to January 1, 2017   July 1, 2017 to January 1, 2018
  ------------------------------------ --------------------------------- ---------------------------------
  Number of patients                   545,478                           552,935
  Age at inclusion (mean, SD)          50.0 (19.1)                       50.1 (19.2)
  Male                                 48.4                              48.5
  ALD Status                           20.0                              20.3
  CMUc Status                          4.9                               4.8
  Zolpidem consumers (N; %; (IC95%))   15,222; 2.79; (2.75--2.83)        8,165; 1.48; (1.44--1.51)

Primary outcome {#sec010}
---------------

### Prevalences {#sec011}

Regarding the variation in prevalence of zolpidem consumers, we observed a decrease from 2.79% to 1.48% ([Table 1](#pone.0228495.t001){ref-type="table"}). This variation in prevalence seemed to be mainly explained by a high number of treatment drops, with a number of patients stopping consumption between the 2 periods (n = 9018) about 4.3 times higher than the number of patients starting during period 2 (n = 2107) ([Table 2](#pone.0228495.t002){ref-type="table"}). The sensitivity analysis showed very similar results (Table in [S1 Table](#pone.0228495.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0228495.t002

###### Mc Nemar test regarding changes in prevalence consumptions.

![](pone.0228495.t002){#pone.0228495.t002g}

  Consumer in period 1   Consumer in period 2                   
  ---------------------- ---------------------- --------------- -------------------
  No                     520,397 (96.81%)       2,107 (0.39%)   522,504 (97.21%)
  Yes                    9,018 (1.68%)          6,004 (1.12%)   15,022 (2.79%)
  Total                  529,415 (98.49%)       8,111 (1.51%)   537,526 (100.00%)

Mc Nemar's Test: Chi-Square 4293.2064; DF 1, p-value \<0.0001

### Incidences {#sec012}

Regarding variation in incidence of new zolpidem treatments we observed a 57% decrease in the incidence of new treatment episodes between the period 1 and the period 2 (from 183 to 79 treatment initiations per 100,000 insured months respectively), with an Incidence Rate Ratio (IRR) of 0.43 (0.38--0.49) ([Fig 1](#pone.0228495.g001){ref-type="fig"}). The announcement of the measure was not associated with a statistically significant decrease in the number of treatment initiations (IRR = 0.92 (0.79--1.08) when comparing the period 1 vs period from January 2017 to April 2017). The decrease became statistically significant only when the measure application became mandatory (IRR = 0.40 (0.34--0.47) when comparing period 1 vs period from April 2017 to July 2017).

![Rates of zolpidem initiations between July 2016 and January 2018.](pone.0228495.g001){#pone.0228495.g001}

Secondary outcome {#sec013}
-----------------

### Evaluation of consumption-associated factors {#sec014}

The characteristics of the population included in the model and the results are described in [Table 3](#pone.0228495.t003){ref-type="table"}. Regarding age, values of odds ratios (OR) ranged from 2.05 (1.86--2.27) for 30-40y old vs 18-30y old comparison to 8.86 (8.09--9.69) for ≥70y old vs 18-30y old comparison. There was also a positive association between being female, benefiting from ALD or CMUc, and the likelihood of receiving zolpidem. On the contrary, a strong negative association was observed between the post change-in-law period (OR = 0.52 (0.51--0.53)) and the likelihood of receiving zolpidem.

10.1371/journal.pone.0228495.t003

###### Results of the multiple logistic regression on patients present in both periods and aged 18 or over in 2016 (N = 535,605).

Being a consumer is predicted.

![](pone.0228495.t003){#pone.0228495.t003g}

  ------------------------------------------------------------------------------------------------------------
  Variable                                     2016\            2017\            Adjusted Odds Ratio (CI95%)
                                               (Size, %)        (Size, %)        
  -------------------------------------------- ---------------- ---------------- -----------------------------
  Age                                                                            

   18-\<30                                     90,052 (16.8)                     Reference

   30-\<40                                     90,210 (16.8)                     2.05 (1.86--2.27)

   40-\<50                                     94,292 (17.6)                     3.75 (3.42--4.12)

   50-\<60                                     90,632 (16.9)                     5.74 (5.25--6.28)

   60-\<70                                     80,537 (15.0)                     7.20 (6.58--7.88)

   70+                                         89,882 (16.8)                     8.86 (8.09--9.69)

  Study period relative to the change in law                                     

   Before                                                                        Reference

   After                                                                         0.52 (0.51--0.53)

  Sex (Female vs Male)                                                           

   Male                                        259,165 (48.4)                    Reference

   Female                                      276,440 (51.6)                    1.67 (1.61--1.72)

  Chronic disease (ALD)                                                          

   No                                          430,649 (80.4)   423,929 (79.2)   Reference

   Yes                                         104,956 (19.6)   111,676 (20.8)   1.98 (1.91--2.05)

  Low income (CMUc)                                                              

   No                                          509,072 (95.0)   510,700 (95.4)   Reference

   Yes                                         26,533 (5.0)     24,905 (4.6)     2.02 (1.90--2.14)
  ------------------------------------------------------------------------------------------------------------

Discussion {#sec015}
==========

We found that the change in law that occurred in the beginning of 2017 regarding zolpidem prescription was concomitant with the halving of the prevalence of zolpidem users. This association was independent of age, sex, from suffering from a chronic disease granting an ALD, and from being precarious enough to benefit from the CMUc scheme. We also observed that the incidence of new zolpidem treatment episodes halved after the promulgation of the law.

The main strength of this study is that we have provided recent population-level data across a representative sample of the exhaustive national reimbursement database. The validity and usefulness of this database in pharmaco-epidemiological studies have been previously studied and validated, and the analysis of large medico-administrative databases offers the advantages of completeness of patients and unbiased study sample \[[@pone.0228495.ref006]\]. The main limitation is the total absence of clinical information, e.g. concerning the effects searched for and felt by patients, the modification in routes of administration, the tolerance and the withdrawal. We have no information either about therapeutic strategies used to reduce zolpidem use. As we rely on a medico-administrative reimbursement database, we have no information on illegal drug use or purchase of zolpidem or other therapies. A complementary in-field study is currently ongoing to document these points \[[@pone.0228495.ref007]\].

These initial results showed that the enforcement of the use of secured prescription sheets had an effect on the population's exposure to zolpidem. Since there are cues that prescription drug abuse varies with the availability of the involved medication \[[@pone.0228495.ref008]\], our results suggest that the change in law could be effective in limiting the entry of new users into abuse or dependence. These results are concordant with observations of primary care pharmacists, albeit in a more restricted area \[[@pone.0228495.ref009]\]. Among the 235 responding pharmacies in the French Rhône area, zolpidem dispensation decreased by an average of 41.8%. On the same time windows, zopiclone dispensations for the 3.75 and 7.5mg dosages increased by 18.4 and 16.7% respectively. Our results were also concordant with another study using the French National Health Insurance database. One year after the information of the ANSM about the measure, the prevalence reimbursement for zolpidem among individuals who had at least one hypnotic drug reimbursement decreased from 26.0% to 18.4%, while the prevalence of reimbursement for zopiclone increased from 18.0% to 28.3% \[[@pone.0228495.ref010]\].

This impact has far exceeded its initial purpose, *i*.*e*. reducing the population of zolpidem misusers. From the practitioners' standpoint, this could be at least partly explained by the manifold ways in which they appropriated this reform.

First, the communication by the health authorities regarding what motivated the measure provided important information regarding risks associated to zolpidem treatment \[[@pone.0228495.ref011],[@pone.0228495.ref012]\]. Following this information, a readjustment by the practitioner of the treatment's benefit/risk balance at the time of its first prescription or renewal could have occurred and could also have triggered open discussions regarding patients' chronic consumptions. For patients considering their consumption as having no negative effects, the fact that a regulatory change occurred for misuse control motives could have been a useful tool for physicians in their discussion to prove the contrary. They may have been to be able to make patients initially reluctant to stop their zolpidem consumption more aware of their problematic use and to agree a try to gradually reduce doses. All this could have led to an increased detection and management of substance use disorders, including withdrawal under medical supervision. This could at least partially explain why the measure has had a far greater impact than initially expected (the proportion of problematic zolpidem user was estimated to 1% of chronic consumers in a previous study)\[[@pone.0228495.ref013]\].

Second, this reform has added constraints to the prescription process of a drug that is often used in clinical practice. The implementation of a less administratively burdensome alternative (e.g. zopiclone) is to be expected, regardless of the treated patients' profile, as general practice consultations last an average of 15 minutes on average \[[@pone.0228495.ref014]\] and an extension of this duration for purely administrative reasons may not be acceptable from a practitioner's point of view. This kind of optimization of consultation time seems all the more plausible as physicians are often over-solicited.

Moreover, adding constraints on the prescription process seems to be more impactful in decreasing drug exposure than simply informing physicians regarding a specific risk \[[@pone.0228495.ref015]\] (e.g. restricting the target population by adding contraindication vs increasing awareness to risks by addition of safety precautions in the summary of the product of a drug) \[[@pone.0228495.ref016]\]. A more appropriate multidimensional approach could have a specific impact on target subgroups, without spilling over into other populations for which the prescription of the drug could have been useful.

From the patients' standpoint, recreational user and self-medicating user profiles may have had different adaptations in the face of the regulatory tightening. As an example, recreational users may have switched to other drugs worse than zolpidem, which may have turned the measure counter-productive in this specific subpopulation. The real impact on patients suffering from zolpidem addiction is still largely unknown and SNDS data do not allow this point to be accurately documented. However, the principles of management of dependence with 'z-drugs' such as zolpidem and zopiclone are the same as the management of benzodiazepine dependence \[[@pone.0228495.ref017]\]. An interesting point would be to monitor the use of other alternative therapies (e.g. zopiclone, benzodiazepines) to better understand the decrease in the use of zolpidem after the measure. Another lead could be to monitor changes in inadequate behavior, such as doctor shopping and use of excessive doses, which already proved to be useful in studying drug misuse using the SNDS database \[[@pone.0228495.ref013],[@pone.0228495.ref018]\]. These investigations are currently conducted. All these point are crucial in order to evaluate if the change-in-law had a beneficial effect, both in terms of individual health and public health.

Regarding the associations between zolpidem consumption and sex, older age, low income and presence of comorbidities, these are consistent with what has already been observed in 2015 on data issued from the same database, but analyzed by another team \[[@pone.0228495.ref019]\]. These associations are also observed in other settings, which suggest that these are not specific to the French population \[[@pone.0228495.ref020],[@pone.0228495.ref021]\]. It should be noted that zolpidem is the most frequently prescribed hypnotic drug in the elderly \[[@pone.0228495.ref019]\], for whom the risk of dependence is high \[[@pone.0228495.ref022],[@pone.0228495.ref023]\]. Studies investigating the evolution of consumption in this specific population are needed.

Secure prescription pads have already been previously implemented in France for other drugs such as flunitrazepam in 2001 and clonazepam in 2011. These regulatory measures were first implemented to reduce misuse, but ultimately had broader implications: reducing the global exposure to the drug in question and changing all other hypnotic drugs prescriptions (e.g. switching to other drugs) \[[@pone.0228495.ref019],[@pone.0228495.ref024]\].

Misuse, abuse or dependence on zolpidem is a worldwide problem \[[@pone.0228495.ref025]--[@pone.0228495.ref027]\]. In France, regulatory changes such as the addition of prescription constraints seem to have a higher impact on prescriptions than the information for physicians. The secured prescription pads used for zolpidem prescription could be replicated in other countries who have to deal with this public health issue. Patients information may be another effective way to reduce the use of zolpidem and especially in countries where drug advertising is allowed (e.g. in United States). Indeed, the expected impact can be considerably modified by the media coverage of the public health decision being implemented \[[@pone.0228495.ref028]--[@pone.0228495.ref030]\].

Conclusions {#sec016}
===========

The enforcement of the use of secured prescription sheets seemed to have decreased French population's exposure to zolpidem. Additional studies on the transfer of consumption to other drugs and the evolution of the type of consumption (chronicity and problematic use) are currently being conducted using the SNDS. Complementary to the use of medico-administrative data, a field study among problematic consumers is still in progress to clinically assess the impacts of the measure. All these components put together form an approach which is the most original to date regarding the evaluation of a measure aiming at limiting hypnotic abuse at a whole country level.

Supporting information {#sec017}
======================

###### Mc Nemar test regarding changes in prevalence consumptions (sensitivity analysis).

(DOC)

###### 

Click here for additional data file.
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Lines 80-82: A lot of acronyms in the Methods, some undefined (OSIAP, SNIIRAM). Can you write out the ones that don\'t appear as frequently in the manuscript (as you have with PMSI and CepiDC)?

Lines 104-106: Date ranges don\'t make sense here. Please clarify. The second one goes (backwards?) from July 2017 to January 2017?

Primary Outcome

Line 167: The use of the term \"significant\" here is confusing \-- unless referring to \"statistical significance\" I would change this term to something else. I also think there is more to be presented here in terms of the sensitivity analysis, instead of just \"no significant changes.\"

Lines 174-178: There may be a more concise way of saying all this. Both sentences seems to be pointing to the same data points, right? Decreasing from 183 to 79 is the 57% decrease? If that is not the case, more clarification is necessary.

Discussion

Line 220: Would again avoid using the term \"addiction\". Dependence is more appropriate. Though I would be careful with use of the term dependence as well. How is it defined, and can your data really show that \"dependence\" among individual users decreased in this large, aggregate data set?

Lines 237-238: \"may have successfully turned patient initially reluctant\" (phrasing here doesn\'t read correctly and should be amended)

Lines 251-252: \"in a current context where the number of active practitioners in France is insufficient to meet the primary care needs.\" (this phrase, though perhaps true, is not relevant to this manuscript and should be deleted)

Lines 253-254: This is an important distinction. It is notable that in the US, a Drug Safety Communication from the FDA did not result in statistically significant changes in prescribing (Kesselheim AS, Donneyong M, Dal Pan GJ, Zhou EH, Avorn J, Schneeweiss S, Seeger JD. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):712-721.) I would ask that the authors cite this paper and discuss the differences between France and the US that may have made secure prescription pads successful in France but DSCs unsuccessful in the US.

Lines 259-260: Please also cite the US paper looking at news media and zolpidem prescribing changes: Woloshin S, Schwartz LM, Dejene S, Rausch P, Dal Pan GJ, Zhou EH, Kesselheim AS. Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis. J Health Commun. 2017 May;22(5):365-372.

Lines 269-271: \"An interesting point would be to monitor the use of long half-life benzodiazepines (e.g diazepam), which could give clues regarding frequency of tapering drug use after the measure\" (I\'m not sure what point is being made here; it should either be clarified further or deleted)

Finally, I\'d like the authors to take some time in the discussion to discuss the broader global implications of such a finding. Have secure prescription pads been used for other drugs in France? What was the outcome? Could this be replicated in a place like the United States, where health systems are far more fragmented? A succinct policy take-home would be nice. As the majority of cites are for French studies, a review of the US (and other EU) literature is warranted.

Conclusion

Lines 284-287: Sentence does not read coherently as written and needs to be rephrased.

Line 285: Would not use the phrase \"abuser profiles\"

Figure 1: Would use the month in the x-axis, not the date as shown. For example, July 2016, not 01/07/2016.

Figure 1: Please label the dashed lines more appropriately. I can\'t tell what 11/01/2017 and 10/04/2017 refer to here (and again, the US/EU conventions for dates leave me confused as to when these events happened.

Reviewer \#2: This study aimed to analyse the effect of a change in French law that categorised Zolpidem to a higher level of prescription control in January 2017. Prior to the law change, Zolpidem use had been associated with tolerance and dependence mechanisms when administered in both a clinical and recreational setting. The law was changed to permit Zolpidem use only with Secure Prescription pads.

Zolpidem is a non-benzodiazepine drug that binds to GABA-A receptors at the same site as traditional benzodiazepines. It acts as an allosteric modulator to potentiate the action of the natural agonist GABA and increase the channel opening frequency allowing chloride ions to enter the cell and hyperpolarise the membrane. The effects of this are varied including, sedation, anxiolysis, anaesthesia and anticonvulsant. Zolpidem being different structurally to benzodiazepines has preference for the alpha-1 subtype of the GABA-A receptor and thus causes a sedation effect without the other benzodiazepine associated effects. Interestingly Zolpidem has been associated in some cases with feelings of euphoria and hallucinations upon administration, an effect distinct from the GABA-A action, when co-administered with BZ, but when BZ was withdrawn, the euphoria persisted \[1\]. Perhaps Zolpidem may show secondary targets.

This informatics study selects data from the General Sample of Beneficaries which is further connected to 3 other databases that banks patient information from over 98% of the French population. Participants of over 18 years of age were selected and data was analysed for 'prevalent users' (users that had been reimbursed for zolpidem at least once before) and 'incident users' (users that has started afresh Zolpidem use). These parameters were compared with factors such as age, sex, health/disease state.

The authors found that the change in law showed a negative correlation with Zolpidem use both in prevalent use and incident use.

Criticisms:

\- The prevalent user data could not be analysed for separate age groups? Dependence in the elderly population may be higher due to reduced half-life of Zolpidem. There are many reports of Zolpidem toxicity in the elderly \[1\]\[2\]\[3\].

\- The authors mention themselves that the study is limited by the lack of information on how use has changed in correlation to use of alternative therapies, which may or may not be more dangerous (such as opioid or benzodiazepine use). Is it possible for the authors to access participant records to check for increase in prescriptions of these to find if there is correlation.

\- The study is also limited in its lack of information regarding drug use/purchase (of both zolpidem or other therapies) outside of the awareness of the medical practitioners prescribing. Has illegal use/purchase of zolpidem increased in this time period?

\- The authors could collect data on users over the period regarding what therapeutic strategies were used to reduce Zolpidem use, perhaps finding correlation with replacement therapies both pharmacological and psychological.

\- Zopiclone is an alternative to Zolpidem and in some European countries is available without prescription. How can we be certain that users are not switching to Zopiclone?

1\. Heydari M, Isfeedvajani MS. Zolpidem dependence, abuse and withdrawal: A case report. J Res Med Sci. 2013;18(11):1006--1007.

2\. Pourshams M, Malakouti SK. Zolpidem abuse and dependency in an elderly patient with major depressive disorder: a case report. Daru. 2014;22(1):54. Published 2014 Jul 10. doi:10.1186/2008-2231-22-54

3\. Styliani, S. , Ioannis, D. , Jannis, N. , Apostolos, I. and Georgios, K. (2009), Zolpidem Dependence in a Geriatric Patient: A Case Report. Journal of the American Geriatrics Society, 57: 1962-1963.
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6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.
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Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: a SNDS database nested cohort study.

PLOS ONE

Dear Dr Caillet,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Both reviewers liked the manuscript and asked to consider modifying some terms, discuss other possible reasons for the decrease in the use of Zolpidem (illegal use, substitution to a over the counter Zopiclone and , the different experience in the US.

Please, address all issues raised and return a revised version for further analysis.

We would appreciate receiving your revised manuscript by Dec 20 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

•A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.

•A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.

•An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Cesario Bianchi

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Access to the French national health insurance database is subject to authorisation from the French National Health Data Institute (Institut National des Données de Santé; INDS, <https://www.indsante.fr/>) and from the French national commission governing the data privacy laws (Commission Nationale Informatique et Liberté; CNIL, <https://www.cnil.fr/>).

3\. Thank you for including your ethics statement:

This study was approved by the local ethic board and the French National Data Protection and Freedoms Committee (number 918201). The study was registered on [www.clinicaltrial.gov](http://www.clinicaltrial.gov) under the number NCT03584542. The study protocol is available as an open publication \[8\].

Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research>.

Additional Editor Comments:

Dear Dr. Caillet,

Your manuscript was reviewed by 2 experts that found it interesting. However, they are asking for several clarifications and the inclusion of additional references.

In particular, both reviewers are concerned about the possibility that the decrease in Zolpedem Use be related to change to other drugs like diazepam (reviewers 1 and 2 and Zopiclone (reviewer 2) that is purcahsed over the counter in some European countries.

Is there an increase in its illegal use? Are there age-groups differences?, etc\...

Many of these questions are still under investigation in the other studies encompassed in the whole ZORRO project. Regarding the specific question of the change in prevalence in zolpidem, by definition (claims data), the database that was used to treat the specific question of the change in prevalence in zolpidem use does not include information regarding OTC purchases and black market. However, we are currently conducting within the ZORRO project other studies specifically design to bring answers regarding switch (including to diazepam), variation of treatment's episodes' length, change in prescription habits from the physician and consumption habits from the patient that occurred after the change in law. Some of these researches use different methodologies (field studies), more suited to their respective objectives. The set of studies that are conducted are described in detail in our published protocol (Gérardin M, Rousselet M, Caillet P, Grall-Bronnec M, Loué P, Jolliet P, et al. French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol. BMJ Open. 2019;9: e027443. doi:10.1136/bmjopen-2018-027443).

Reviewer 1 is also asking to make a comparison between US and France because the US experience seems to be different. The reviewer has many concerns about some terms use like addition vs dependence.

Both reviewers asked to include some references relevant to the topic.

We added references and modified our manuscript accordingly.

Please, carefully address every issue raised and make changes if find necessary, in your revised version.

Thank you,

Cesario Bianchi

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: N/A

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Overall a nice paper demonstrating that a French government intervention had its intended effect of decreasing prescriptions of the drug zolpidem due to concerns about dependence. Contrasts with the US experience related to Drug Safety Communications and zolpidem prescribing.

Abstract

Lines 16-17: Not really a comment limited to the Abstract, but why only 6 months pre- and post-?

The first communication of ANSM about the measure took place in January 2017 and the application of the decree in April 2017. We therefore chose the beginning of the post-period when we thought that zolpidem consumption would have stabilized, i.e. in July 2017. In order to neutralize a potential seasonal effect, we sought to have the same monthly composition for each comparative period. So, each of the two comparative periods begins on July and ends on January (6-month period).

Introduction

Line 46: Would not use the term \"addict patients,\" that term has fallen out of favor in the US and elsewhere. Suggest sticking to the term dependent as it was used earlier in the same sentence

We have amended the text accordingly.

Lines 48-49: Should read \"increased their doses considerably\" \-- but please clarify what is meant by considerably. Do you mean 2.5 mg to 10 mg? If so I\'m not sure that\'s a considerable increase since it\'s within the recommended dose range and patients are generally titrated up to achieve therapeutic effect

We have deleted "considerably" as it was confusing. In Victorri-Vigneau et al. \[4\], French reports of dependence to zolpidem reported an increase in zolpidem doses to high doses: mean ranging from 94mg to 265mg between 2004 and 2010.

Line 57: Please explain what \"secure prescription pads\" are. We don\'t have them in the United States, but this is an interesting concept and may have promise in the US depending on what they are and how they are utilized in France. Without a clear definition, it\'s hard to determine the broader applicability of these findings.

We have added an explanation on "secure prescription pads" in the Introduction section:

In light of these results, the prescription of zolpidem on secure prescription pads was put forward by the French National Commission on Narcotics and Psychotropic Substances. Secured prescription pads contains specific prescription sheets that are protected against forgery and that must be used by physicians when prescribing narcotics. On the 11th of January 2017, the ANSM decreed that as from April the 10th 2017, the prescription of zolpidem was to be done with such secured prescription pads in order to limit the risk of abuse and misuse. Moreover, such prescription must now display the number of therapeutic units, quantity and dosage written in full and for a maximum duration of 28 days.

Materials and Methods

Lines 80-82: A lot of acronyms in the Methods, some undefined (OSIAP, SNIIRAM). Can you write out the ones that don\'t appear as frequently in the manuscript (as you have with PMSI and CepiDC)?

We have written out the acronyms OSIAP, SNIIRAM and CNSP in full in the Introduction and the Materials and methods sections.

Lines 104-106: Date ranges don\'t make sense here. Please clarify. The second one goes (backwards?) from July 2017 to January 2017?

The second period is July 2017 to January 2018. We have made the change in the Materials and methods section.

Primary Outcome

Line 167: The use of the term \"significant\" here is confusing \-- unless referring to \"statistical significance\" I would change this term to something else. I also think there is more to be presented here in terms of the sensitivity analysis, instead of just \"no significant changes.\"

We agree with your point. We have changed the term in Results and added the results of sensitivity analysis as a supplementary table (S1 Table).

Lines 174-178: There may be a more concise way of saying all this. Both sentences seems to be pointing to the same data points, right? Decreasing from 183 to 79 is the 57% decrease? If that is not the case, more clarification is necessary.

Indeed, the two sentences repeated the same data points. We made the clarification in the Results section.

Discussion

Line 220: Would again avoid using the term \"addiction\". Dependence is more appropriate. Though I would be careful with use of the term dependence as well. How is it defined, and can your data really show that \"dependence\" among individual users decreased in this large, aggregate data set?

We agree with your comment. According to Diagnostic and Statistical Manual of Mental Disorders, 5th edition, dependence is usually defined using clinical criteria which are not available in medico-administrative data (e.g. tolerance, withdrawal). Consequently, we are not able to show a decrease of dependence to zolpidem clinically from our medico-administrative data. However, the decrease in the availability of the substance through the enforcement of the use of secured prescription sheets will possibly decrease the abuse and dependence to zolpidem. We will investigate this finding in the additional field study. We have changed the term "addiction" and moderated our phrasing in the Discussion section regarding to the lack of clinical data.

Lines 237-238: \"may have successfully turned patient initially reluctant\" (phrasing here doesn\'t read correctly and should be amended)

We have amended the phrasing to make it clearer.

Lines 251-252: \"in a current context where the number of active practitioners in France is insufficient to meet the primary care needs.\" (this phrase, though perhaps true, is not relevant to this manuscript and should be deleted)

We have deleted this phrase.

Lines 253-254: This is an important distinction. It is notable that in the US, a Drug Safety Communication from the FDA did not result in statistically significant changes in prescribing (Kesselheim AS, Donneyong M, Dal Pan GJ, Zhou EH, Avorn J, Schneeweiss S, Seeger JD. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):712-721.) I would ask that the authors cite this paper and discuss the differences between France and the US that may have made secure prescription pads successful in France but DSCs unsuccessful in the US.

Secure prescription pads and Drug Safety Communications are completely different. In France, the use of secure prescription pads for some drugs is required by the law. It implies that a drug must be prescribed on a particular prescription support which is protected against forgery. This measure adds constraints on the prescription process. We have added the reference in our explanation on the difference between adding prescribing constraints and informing physicians about drug use. We have also explained secure prescription pads in the Introduction section.

Lines 259-260: Please also cite the US paper looking at news media and zolpidem prescribing changes: Woloshin S, Schwartz LM, Dejene S, Rausch P, Dal Pan GJ, Zhou EH, Kesselheim AS. Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis. J Health Commun. 2017 May;22(5):365-372.

We have added this paper in our references.

Lines 269-271: \"An interesting point would be to monitor the use of long half-life benzodiazepines (e.g diazepam), which could give clues regarding frequency of tapering drug use after the measure\" (I\'m not sure what point is being made here; it should either be clarified further or deleted)

In this phrase, we wanted to explain that investigating the switches from zolpidem to other drugs after the measure is the key to understanding the decrease in use of zolpidem. Indeed, Touchard et al. showed an increase in prevalence of zopiclone reimbursements one year after the measure. This paper was published after our first submission to Plos One and has been added to references (number 10). Monitoring the use of alternative therapies (e.g. zopiclone, benzodiazepines...) after the measure will be the subject of a forthcoming publication. We have explained this point in more detail in the Discussion section.

Finally, I\'d like the authors to take some time in the discussion to discuss the broader global implications of such a finding. Have secure prescription pads been used for other drugs in France? What was the outcome? Could this be replicated in a place like the United States, where health systems are far more fragmented? A succinct policy take-home would be nice. As the majority of cites are for French studies, a review of the US (and other EU) literature is warranted.

We have added a part in the Discussion to detail broader implications of the regulatory change and the previously use of prescription pads in France. We have also mentioned the potential to replication in other countries or other potential keys to reduce zolpidem use.

Conclusion

Lines 284-287: Sentence does not read coherently as written and needs to be rephrased.

We have rephrased it in a more comprehensive way.

Line 285: Would not use the phrase \"abuser profiles\"

We have changed the term "abuser profiles".

Figure 1: Would use the month in the x-axis, not the date as shown. For example, July 2016, not 01/07/2016.

We have made the changes in the x-axis in Figure 1.

Figure 1: Please label the dashed lines more appropriately. I can\'t tell what 11/01/2017 and 10/04/2017 refer to here (and again, the US/EU conventions for dates leave me confused as to when these events happened.

We have made changes in labels of the dashed lines and changed the date format to make Figure 1 clearer.

Reviewer \#2: This study aimed to analyse the effect of a change in French law that categorised Zolpidem to a higher level of prescription control in January 2017. Prior to the law change, Zolpidem use had been associated with tolerance and dependence mechanisms when administered in both a clinical and recreational setting. The law was changed to permit Zolpidem use only with Secure Prescription pads.

Zolpidem is a non-benzodiazepine drug that binds to GABA-A receptors at the same site as traditional benzodiazepines. It acts as an allosteric modulator to potentiate the action of the natural agonist GABA and increase the channel opening frequency allowing chloride ions to enter the cell and hyperpolarise the membrane. The effects of this are varied including, sedation, anxiolysis, anaesthesia and anticonvulsant. Zolpidem being different structurally to benzodiazepines has preference for the alpha-1 subtype of the GABA-A receptor and thus causes a sedation effect without the other benzodiazepine associated effects. Interestingly Zolpidem has been associated in some cases with feelings of euphoria and hallucinations upon administration, an effect distinct from the GABA-A action, when co-administered with BZ, but when BZ was withdrawn, the euphoria persisted \[1\]. Perhaps Zolpidem may show secondary targets.

This informatics study selects data from the General Sample of Beneficaries which is further connected to 3 other databases that banks patient information from over 98% of the French population. Participants of over 18 years of age were selected and data was analysed for 'prevalent users' (users that had been reimbursed for zolpidem at least once before) and 'incident users' (users that has started afresh Zolpidem use). These parameters were compared with factors such as age, sex, health/disease state.

The authors found that the change in law showed a negative correlation with Zolpidem use both in prevalent use and incident use.

Criticisms:

\- The prevalent user data could not be analysed for separate age groups? Dependence in the elderly population may be higher due to reduced half-life of Zolpidem. There are many reports of Zolpidem toxicity in the elderly \[1\]\[2\]\[3\].

We agree with your comment. Dependence in the elderly is a major of concern. We included age groups in the multiple logistic regression (Table 3). Age was positively associated to zolpidem consumption with a very excess of risk of zolpidem consumption in the elderly population: OR = 8.86 \[8.09-9.69\] for ≥70y old vs 18-30y old. This finding highlights the need to further study the impact of the measure in the elderly population. A project is in currently in progress to study benzodiazepines and Z-drugs consumption in the elderly population including a focus on the evolution of zolpidem consumption after the measure. We have added a point about the elderly population in the Discussion section.

\- The authors mention themselves that the study is limited by the lack of information on how use has changed in correlation to use of alternative therapies, which may or may not be more dangerous (such as opioid or benzodiazepine use). Is it possible for the authors to access participant records to check for increase in prescriptions of these to find if there is correlation.

We agree with your comment. Studying the use of alternative therapies is the key to understanding the decrease of zolpidem use after the measure. In the French national health insurance database, we have information about reimbursed drug deliveries. So, we can study treatment transfers to other drugs (e.g. benzodiazepines, zopiclone...). Touchard et al. \[10\] recently published an increase in the prevalence of zopiclone reimbursements one year after the measure using the medico-administrative database. Monitoring the use of alternative therapies (e.g. zopiclone, benzodiazepines...) after the measure will be the subject of a forthcoming publication. We have made a clarification about this point in the Discussion section.

\- The study is also limited in its lack of information regarding drug use/purchase (of both zolpidem or other therapies) outside of the awareness of the medical practitioners prescribing. Has illegal use/purchase of zolpidem increased in this time period?

We don't have the information of the evolution of illegal use or purchase in the study period yet. These results will be available in our further national survey of forged prescription sheets OSIAP (Suspect Prescriptions Possibly Indicating Abuse or "Ordonnances Suspectes Indicateur d'Abus Possible" in French). Moreover, this will be also investigated in the field study. We have added this point in the Discussion section.

\- The authors could collect data on users over the period regarding what therapeutic strategies were used to reduce Zolpidem use, perhaps finding correlation with replacement therapies both pharmacological and psychological.

In the French National Health Insurance data, we cannot identify pharmacological and psychological therapeutic strategies to reduce zolpidem use. We agree that this is a very important point in order to understand fully the decrease in zolpidem use after the measure and this will investigated in our field study among problematic users and general practitioners. We have added a precision about this point in the Discussion section.

\- Zopiclone is an alternative to Zolpidem and in some European countries is available without prescription. How can we be certain that users are not switching to Zopiclone?

Zopiclone is indeed an alternative to zolpidem. Touchard et al. described an increase in prevalence of zopiclone one year after the measure. Thus, the switch from zolpidem to zopiclone may explain part of the observed decrease in zolpidem use. In a study that we are currently conducting, we planned to monitor the use of alternative therapies such as zopiclone or benzodiazepines in order to distinguish the switch to other drugs from the complete stop of hypnotic drug use. We have explained this in more detail in the Discussion section.

###### 

Submitted filename: 2019-12-13_Rebuttal.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0228495.r003

Decision Letter 1

Bianchi

Cesario

Academic Editor

© 2020 Cesario Bianchi

2020

Cesario Bianchi

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

17 Jan 2020

Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: a SNDS database nested cohort study.

PONE-D-19-22052R1

Dear Dr. Caillet,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Cesario Bianchi

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Dear Dr. Caillet,

Thank you for carefully revising your manuscript that I now find acceptable for publication.

Please check the minor comments of reviewer 2, recommending further English editing.

thank you

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: Thank you for addressing our reviewing comments, we recommend that you check some grammatical errors in the manuscript before publication. Sometimes you have used patient in singular forms instead of the required plural form. Also limit should be referred to as limitations.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: Yes: Gilberto DeNucci, Charles Serpellone Nash

10.1371/journal.pone.0228495.r004

Acceptance letter

Bianchi

Cesario

Academic Editor

© 2020 Cesario Bianchi

2020

Cesario Bianchi

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

7 Feb 2020

PONE-D-19-22052R1

Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: a SNDS database nested cohort study.

Dear Dr. Caillet:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Cesario Bianchi

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
